v3.26.1
Description of Organization and Business Operations (Tables)
12 Months Ended
Dec. 31, 2025
Titan Pharmaceuticals Inc [Member]  
Schedule of Antidilutive Securities Excluded from Computation of Net Loss Per Common Share

       
   December 31, 
   2025   2024 
Weighted-average anti-dilutive common shares resulting from convertible preferred stock   -    593 
Weighted-average anti-dilutive common shares resulting from convertible notes   -    7 
Weighted-average anti-dilutive common shares resulting from stock options and awards   -    92 
Weighted-average anti-dilutive common shares resulting from warrants   -    477 
Anti-dilutive Securities Excluded from Computation of Earnings Per Share, Amount   -    1,169